ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease

For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT-2i) are associated with reduced risk of cardiovascular (CV) events compared with dipeptidyl peptidase 4 inhibitors (DPP-4i), according to a study presented at the annual meeting of the Endocrine Society, held from June 1 to 4 in Boston.

Alexander Kutz, M.D., M.P.H., from Brigham and Women’s Hospital and Harvard Medical School in Boston, and colleagues used pooled data from Medicare fee-for-service and a large U.S. health insurance database to examine the comparative CV and hepatic effectiveness and safety of GLP-1 RA and SLGT-2i in people with T2D and prevalent MASLD.

Source: Advances and More licensed by HealthDay